.jpg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=h:100){kind=logo}
The Problem
Seizures are unpredictable, disruptive and can lead to injury. People with epilepsy frequently do not recognize they have had a seizure. Family members despite being very vigilant do not always have eyes on their loved ones with epilepsy and can miss seizures.
Doctors prescribe medicines, anticonvulsants to prevent seizures. However, since seizures are hard to count it can be difficult to find the right dose of the anticonvulsants to control the seizures.
Simply put, monitoring seizures outside of the hospital is like monitoring a fever without a thermometer.
Existing Solutions
Hovering
EEG-Based Wearables
EEG-Based Wearables
Constant observation of a loved one with epilepsy including co-sleeping identifies only 50% of the seizures. Hovering results in a lot of stress on families and the person with epilepsy are left feeling "sick or different"
EEG-Based Wearables
EEG-Based Wearables
EEG-Based Wearables
EEG solutions with fewer electrodes than a full EEG still require physician review and cannot differentiate clinical seizures from the signature of epilepsy.
Digital Wearables
EEG-Based Wearables
Digital Wearables
These types of solutions are able to detect convulsive seizures which make up about 20% of seizure types.
The Solution
Our seizure detection software software algorithm uses oculometric data (i.e, eye movements) to reliably detect a seizure. By employing machine learning capabilities, our software will also be able to predict when a seizure will occur. We expect our software to easily interface and/or integrate with consumer grade eye-tracking systems (eg. smart glasses) and therapeutic devices (eg. neuromodulation).
The Competitive Advantage
It is expected that all seizure types will be detected using a personalized solution for personalized treatments.
The Opportunity
Potentially, there are several opportunities to help revolutionize epilepsy care:
- Eysz is expecting to quantitate in real time, side effects such as sedation and slowed cognition related to epilepsy and its treatment empowering patients and their physicians with data to make informed medical decisions.
- Eysz has the potential to alter the treatment landscape by collaborating with manufacturers of neuromodulation systems and pharmaceuticals for epilepsy. For example, Eysz has the potential to improve the biomarkers used in closed loop neuro-modulation systems such as the vagal nerve stimulator which currently rely on a heart rate, a biomarker which is approximately 70% accurate.
- Eysz has the potential to provide epileptic drug manufacturers with accurate seizure counts and side effect detection during clinical studies improving the quality of safety and efficacy data.
The Preliminary Evidence
We recently completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.
Our Team
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Jit Sarkar, Co-Founder and CTO
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Parth Amin, Co-Founder and Chief Commercial Officer
Parth Amin, Co-Founder and Chief Commercial Officer
Parth Amin, Co-Founder and Chief Commercial Officer
Experienced clinical device development and go-to-market strategist with 15+ years of global medical device and partnership experience. Currently develops and manages our partner ecosystem.
Nicolle Napier - Ionascu Chief Neuropsychologist
Parth Amin, Co-Founder and Chief Commercial Officer
Parth Amin, Co-Founder and Chief Commercial Officer
Leads the Eysz cognitive research team. Practicing neuropsychology for over 12 years primarily in the Bay Area. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland
Our Advisors
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles and 4 books. He was named 1996-2016 in Best Doctors in America. He received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award.
Hal Blumenfeld, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Dr. Blumenfeld's clinical and research work focuses on epilepsy, cognition and brain imaging. He directs Yale's Clinical Neuroscience Imaging Center (CNIC), a new multi-disciplinary core facility for innovative study and treatment of brain disorders. Teaching activities include a textbook titled Neuroanatomy Through Clinical Cases, Sinauer Assoc., Publ. 2002, 2010.
Peter Milford, PhD Technical Advisor
Peter Milford, PhD Technical Advisor
Peter Milford, PhD Technical Advisor
Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology, up until October 2016, when purchased by Google. He continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets. He now serves as the President of Parallel Rules consulting firm.
Steve Duddy Business Advisor
Peter Milford, PhD Technical Advisor
Peter Milford, PhD Technical Advisor
Steve brings 30+ years of leadership and strategy experience in the Medical Device industry. He has held a variety of leadership roles in various cross functional areas. Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis. Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets.
Board of Directors
Randy Berholtz JD, MBA
Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives. He currently services as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners. He is also a parent of a child with epilepsy.